{"id":742154,"date":"2012-12-18T07:30:00","date_gmt":"2012-12-18T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/"},"modified":"2023-03-22T00:04:20","modified_gmt":"2023-03-22T04:04:20","slug":"merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/","title":{"rendered":"Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      and GE Healthcare today announced a clinical study collaboration,<br \/>\n      license and supply agreement for use of [<sup>18<\/sup>F]Flutemetamol, an<br \/>\n      investigational positron emission tomography (PET) imaging agent, to<br \/>\n      support Merck&#8217;s development of MK-8931, a novel oral beta amyloid<br \/>\n      precursor protein site cleaving enzyme (BACE) inhibitor and Merck&#8217;s lead<br \/>\n      investigational candidate for Alzheimer&#8217;s disease (AD).\n    <\/p>\n<p>\n      Accumulation of beta amyloid in the brain is a pathological<br \/>\n      characteristic related to Alzheimer\u2019s disease. Currently, AD is<br \/>\n      diagnosed by clinical examination (i.e., medical history, physical,<br \/>\n      neurological, psychiatric and neuropsychological exams, laboratory tests<br \/>\n      and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan).<br \/>\n      An AD diagnosis can only be confirmed through histopathological<br \/>\n      identification of characteristic features, including beta amyloid<br \/>\n      plaques, in post-mortem brain samples.\n    <\/p>\n<p>\n      &#8220;There is a serious unmet need for a reliable method for measuring beta<br \/>\n      amyloid deposits to help physicians diagnose Alzheimer\u2019s disease at its<br \/>\n      different stages and study its progression,&#8221; said Darryle Schoepp,<br \/>\n      Ph.D., senior vice president, head of neuroscience and ophthalmology,<br \/>\n      Merck Research Laboratories. &#8220;This agreement will allow us to employ an<br \/>\n      investigational imaging agent to help identify patients who might<br \/>\n      benefit from an anti-amyloid therapy and enable clinical evaluation of<br \/>\n      our lead BACE inhibitor candidate for Alzheimer&#8217;s disease, MK-8931.&#8221;\n    <\/p>\n<p>\n      Under the agreement, GE Healthcare will supply [<sup>18<\/sup>F]Flutemetamol<br \/>\n      to help select patients for clinical trials and evaluate this<br \/>\n      investigational agent as a companion diagnostic tool. A joint Merck and<br \/>\n      GE Healthcare Imaging Advisory Committee will oversee the planned<br \/>\n      imaging studies.\n    <\/p>\n<p>\n      \u201cIn clinical trials, [<sup>18<\/sup>F]Flutemetamol demonstrated<br \/>\n      consistent performance in the visual detection of beta amyloid in the<br \/>\n      brain when compared with histopathology data,\u201d said Jonathan Allis,<br \/>\n      general manager, PET, GE Healthcare Medical Diagnostics. \u201c[<sup>18<\/sup>F]Flutemetamol<br \/>\n      imaging has the potential to be part of a larger diagnostic workup that<br \/>\n      may help doctors rule out Alzheimer\u2019s disease by reliably showing the<br \/>\n      absence of amyloid deposits in patients with unexplained loss of<br \/>\n      cognitive function.\u201d\n    <\/p>\n<p>\n      <b>About Merck\u2019s BACE Inhibitor Development Program and MK-8931<\/b>\n    <\/p>\n<p>\n      Merck is advancing several innovative programs in Alzheimer&#8217;s disease,<br \/>\n      including candidates designed to modify disease progression as well as<br \/>\n      improve symptom control. Merck&#8217;s lead candidate in disease modification<br \/>\n      is MK-8931, an investigational oral BACE inhibitor.\n    <\/p>\n<p>\n      Results of Phase I clinical studies demonstrated that MK-8931 can reduce<br \/>\n      cerebral spinal fluid (CSF) beta amyloid by greater than 90 percent in<br \/>\n      healthy volunteers without dose limiting side effects. Based on these<br \/>\n      results, Merck is moving forward with a global, multi-center Phase<br \/>\n      II\/III clinical trial, called EPOCH, to evaluate the safety and efficacy<br \/>\n      of MK-8931 versus placebo in patients with mild-to-moderate AD. For more<br \/>\n      information about the EPOCH study please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.ADstudyinfo.com&#038;esheet=50511095&#038;lan=en-US&#038;anchor=www.ADstudyinfo.com&#038;index=1&#038;md5=f5579c18f9030a12c9b423925b79c86c\">www.ADstudyinfo.com<\/a><br \/>\n      or call 1-855-55-EPOCH (37624). Information is also available at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.clinicaltrials.gov&#038;esheet=50511095&#038;lan=en-US&#038;anchor=www.clinicaltrials.gov&#038;index=2&#038;md5=373cdc75968ce892db12c244d029125f\">www.clinicaltrials.gov<\/a><span class=\"bwuline\">.<\/span>\n    <\/p>\n<p>\n      <b>About [<\/b><sup><b>18<\/b><\/sup><b>F]Flutemetamol<\/b>\n    <\/p>\n<p>\n      [<sup>18<\/sup>F]Flutemetamol is an investigational PET imaging agent<br \/>\n      being developed by GE Healthcare for the detection of beta amyloid<br \/>\n      deposits in the brain. Pooled results from Phase III brain autopsy and<br \/>\n      biopsy studies showed a strong concordance between [18F]Flutemetamol<br \/>\n      images and AD-associated beta amyloid brain pathology. Phase III studies<br \/>\n      demonstrated [18F]Flutemetamol visual detection of beta amyloid with a<br \/>\n      majority read sensitivity of 86 percent and specificity of 92 percent.\n    <\/p>\n<p>\n      <b>About Alzheimer&#8217;s Disease and Amyloid Hypothesis<\/b>\n    <\/p>\n<p>\n      Alzheimer\u2019s disease (AD) is a devastating, irreversible and ultimately<br \/>\n      fatal disease that progressively destroys neurons in the brain, leading<br \/>\n      to a deterioration of cognitive function. The symptoms include loss of<br \/>\n      memory that progresses into behavioral changes, alterations in thinking<br \/>\n      and reasoning skills that interfere with daily activities, and dementia.<br \/>\n      AD is the most common cause of dementia, accounting for approximately<br \/>\n      50-75 percent of the estimated 35 million dementia cases globally.<sup>1,2<\/sup><br \/>\n      About 5.4 million people in the United States are currently living with<br \/>\n      AD.<sup>3<\/sup> There are currently no disease-modifying treatments<br \/>\n      available for AD, and current treatment options are limited to providing<br \/>\n      symptomatic improvements with only modest and short-term effects.\n    <\/p>\n<p>\n      While the exact cause of AD remains unknown, a current prevailing theory<br \/>\n      asserts that AD occurs due to the accumulation of beta amyloid proteins<br \/>\n      in the brain. Beta amyloid precursor protein site cleaving enzyme (BACE)<br \/>\n      is believed to be a key enzyme in the production of beta amyloid<br \/>\n      peptide. Evidence suggests that inhibiting BACE decreases the production<br \/>\n      of beta amyloid and may therefore reduce amyloid plaque formation and<br \/>\n      modify disease progression.\n    <\/p>\n<p>\n      <b>ABOUT GE HEALTHCARE<\/b>\n    <\/p>\n<p>\n      GE Healthcare provides transformational medical technologies and<br \/>\n      services that are shaping a new age of patient care. Our\u00a0broad expertise<br \/>\n      in medical imaging and information technologies, medical diagnostics,<br \/>\n      patient monitoring systems, drug discovery, biopharmaceutical<br \/>\n      manufacturing technologies, performance improvement,\u00a0and performance<br \/>\n      solutions services helps\u00a0our customers deliver better care to more<br \/>\n      people around the world at a lower cost. In addition, we\u00a0partner\u00a0with<br \/>\n      healthcare leaders, striving to\u00a0leverage the global policy change<br \/>\n      necessary to implement\u00a0a successful shift to sustainable healthcare<br \/>\n      systems.\n    <\/p>\n<p>\n      Our &#8220;healthymagination&#8221; vision for the future invites the world to\u00a0join<br \/>\n      us on our journey as we continuously develop innovations focused on<br \/>\n      reducing costs, increasing access,\u00a0and improving quality around the<br \/>\n      world. Headquartered in the United Kingdom, GE Healthcare is a unit of<br \/>\n      General Electric Company (NYSE: GE). Worldwide, GE Healthcare\u00a0employees<br \/>\n      are committed to serving healthcare professionals and their patients in<br \/>\n      more than 100 countries. For more information about GE Healthcare, visit<br \/>\n      our web site at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.gehealthcare.com%2Fwww.gehealthcare.com&#038;esheet=50511095&#038;lan=en-US&#038;anchor=www.gehealthcare.com&#038;index=3&#038;md5=a511dc45bd85be610a22323bff95a713\">www.gehealthcare.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50511095&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=4&#038;md5=c423ce3a1828e382f34ce1ac9af72ac6\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. If underlying<br \/>\n      assumptions prove inaccurate or risks or uncertainties materialize,<br \/>\n      actual results may differ materially from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50511095&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=5&#038;md5=46ab60bf6668be3a36cf6e0bdaba0f74\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <sup>1<\/sup> Alzheimer\u2019s Disease International. Types of Dementia:<br \/>\n      Alzheimer\u2019s Disease. Available at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.alz.co.uk%2Finfo%2Falzheimers-disease&#038;esheet=50511095&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.alz.co.uk%2Finfo%2Falzheimers-disease&#038;index=6&#038;md5=d564c7738e049a7f257251f90654f2f0\">http:\/\/www.alz.co.uk\/info\/alzheimers-disease<\/a>.\n    <\/p>\n<p>\n      <sup>2<\/sup> Alzheimer\u2019s Disease International. Dementia Statistics.<br \/>\n      Available at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.alz.co.uk%2Fresearch%2Fstatistics&#038;esheet=50511095&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.alz.co.uk%2Fresearch%2Fstatistics&#038;index=7&#038;md5=3ade114a9e35dfbb439e40b69810149a\">http:\/\/www.alz.co.uk\/research\/statistics<\/a>.\n    <\/p>\n<p>\n      <sup>3<\/sup> Alzheimer\u2019s Association. Alzheimer\u2019s Fact and Figures.<br \/>\n      Available at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.alz.org%2Falzheimers_disease_facts_and_figures.asp&#038;esheet=50511095&#038;lan=en-US&#038;anchor=http%3A%2F%2Fwww.alz.org%2Falzheimers_disease_facts_and_figures.asp&#038;index=8&#038;md5=539c791ee73888a4ef93ea7862159915\">http:\/\/www.alz.org\/alzheimers_disease_facts_and_figures.asp<\/a>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20121218005719r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20121218005719\/en\/\">http:\/\/www.businesswire.com\/multimedia\/home\/20121218005719\/en\/<\/a><\/span><\/p>\n<p>       Media Contacts:<br \/>Merck<br \/>Caroline Lappetito, 267-305-7639<br \/>or<br \/>GE<br \/>Aleisia        Gibson, 201-289-3832<br \/>or<br \/>Investor Relations Contacts:<br \/>Merck<br \/>Carol        Ferguson, 908-423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [ 18 F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck&#8217;s development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck&#8217;s lead investigational candidate for Alzheimer&#8217;s disease (AD). Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer\u2019s disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples. &#8220;There is a serious unmet<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289,56],"class_list":["post-742154","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [ 18 F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck&#039;s development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck&#039;s lead investigational candidate for Alzheimer&#039;s disease (AD). Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer\u2019s disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples. &quot;There is a serious unmet\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:20+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121218005719r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\\\/\",\"name\":\"Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121218005719r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2012-12-18T07:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121218005719r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121218005719r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/","og_locale":"en_US","og_type":"article","og_title":"Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [ 18 F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD). Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer\u2019s disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples. \"There is a serious unmet","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:20+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121218005719r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/","name":"Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121218005719r1&sid=sfsite1&distro=nx","datePublished":"2012-12-18T07:30:00+00:00","dateModified":"2023-03-22T04:04:20+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121218005719r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121218005719r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-ge-healthcare-collaborate-on-use-of-imaging-biomarkers-for-investigational-bace-inhibitor-clinical-development-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and GE Healthcare Collaborate on Use of Imaging Biomarkers for Investigational BACE inhibitor Clinical Development Program"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ea82d060-7b63-4e97-a633-7fd227c4fe4e","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742154\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742154"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}